Asthma Indicators for LHIN 12: North Simcoe Muskoka

	Asthma Indicators for LHIN 12: North Simcoe Muskoka																						
Indicator	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017*	2018*
1. PFT used for diagnosis (% of incident asthma)†	47.68	46.52	45.85	44.48	46.51	49.47	49.05	44.95	50.76	52.75	55.21	55.80	56.05	57.57	60.99	60.05	60.16	58.63	60.05	66.38	64.86	61.64	59.83
2. PFT used for monitoring (% of prevalent asthma)†	13.30	11.36	10.57	9.58	8.69	8.61	8.04	7.29	7.29	7.22	7.19	6.93	6.66	6.61	6.78	6.81	6.48	6.08	6.03	6.01	6.40	6.41	6.13
3. ≥1 ICS prescription (% of prevalent asthma)‡	58.54	56.57	55.49	53.80	53.02	52.87	51.38	49.72	49.41	48.76	48.62	48.36	48.29	47.72	48.68	48.85	48.01	48.79	46.88	47.92	46.71	43.61	40.46
4. ≥1 β2-agonist prescription (% of prevalent asthma)‡	64.14	61.59	59.60	57.94	56.91	54.42	52.25	50.81	49.12	47.07	45.42	43.92	41.74	40.00	40.35	39.67	37.31	37.52	35.52	25.73	25.60	24.30	23.80
5. ≥1 asthma ED visit (% of prevalent asthma)	8.01	7.13	5.72	5.43	5.13	4.28	3.89	3.06	3.16	2.80	2.63	2.48	2.15	1.93	1.69	1.54	1.34	1.40	1.26	1.28	1.14	1.09	1.07
6. ≥1 asthma physician office visit (% of prevalent asthma)	33.90	31.00	28.46	27.07	24.83	24.13	21.94	20.01	19.48	18.68	17.41	16.39	14.24	12.95	12.49	11.62	10.84	10.43	9.95	9.78	9.48	9.14	9.15
7. β2-agonist use (% of prevalent asthma)‡																							
0	35.86	38.41	40.40	42.06	43.09	45.58	47.75	49.19	50.88	52.93	54.58	56.08	58.26	60.00	59.65	60.33	62.69	62.48	64.48	74.27	74.40	75.70	76.20
1-2	17.43	17.83	17.16	16.33	17.25	17.22	17.02	17.68	16.48	17.58	17.78	17.36	17.58	17.18	17.63	17.71	16.56	18.10	16.58	12.21	12.54	11.64	11.36
≥3	46.71	43.76	42.44	41.61	39.66	37.20	35.23	33.13	32.64	29.49	27.63	26.56	24.16	22.82	22.73	21.96	20.75	19.42	18.94	13.52	13.07	12.66	12.44

^{*}Reporting period is from April 1996 to March 2019. Data for 2017 and 2018 may be incomplete due to the 2-year algorithm to identify asthma, and numbers are subject to change.

PFT = pulmonary function test; ICS = inhaled corticosteroid; ED = emergency department; ODB = Ontario Drug Benefit; OHIP = Ontario Health Insurance Plan; LHIN = Local Health Integration Network; HSU = health services use †PFT data refers to individuals aged 7-99 years in the asthma prevalent population.

‡Drug use data refers to individuals aged 66-99 years with complete year ODB coverage in the asthma prevalent population.

Technical notes:

Asthma indicators - detailed description:

- 1. Percent of asthma incidence aged 7 years and above with a PFT in one year prior to or 2.5 years after incidence date^{a-c}
- 2. Percent of asthma prevalence aged 7 years and above with a PFT in one year prior to the index date^{a,c-e}
- 3. Percent of asthma prevalence 66 years and above with at least one prescription of ICS in one year prior to the index date^{c-e}
- 4. Percent of asthma prevalence aged 66 years and above with at least one prescription of β 2-agonist in one year prior to the index date^{c-e}
- 5. Percent of asthma prevalence with at least one ED visit in one year prior to the index date^{c-e}
- 6. Percent of asthma prevalence with at least one physician office visit in one year prior to the index date^{c-e}
- 7. Distribution of the three categories of β 2-agonist use for asthma prevalence aged 66 years and above^{c,d}

Source: This table uses statistics reported by the Ontario Asthma Surveillance Information System (OASIS) and data provided by ICES, Ontario.

^aOHIP data was up to December 2019 when the tables were created.

^bFor asthma incidence from July 2017 to March 2019, PFT data for 2.5-year post asthma incidence are not complete as latest data were available up to December 2019 when the tables were created.

^cIndividuals with missing LHIN, rurality, or without OHIP coverage were excluded.

^dAsthma incidence of the year were excluded from this table, except for indicator 1.

elndex date is defined as the first service date of asthma HSU, or any HSU if there was no asthma HSU, or April 1 if there was no HSU during the year.